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Methods: Three topographic staging schemes for tau PET, two sampling the temporal and occipital
subregions only and one sampling cortical gray matter across the major brain lobes, were evaluated
on flortaucipir F 18 PET images in a test-retest scenario and fromAlzheimer’s Disease Neuroimaging
Initiative 2.
Results: All three schemes estimated stages that were significantly associated with amyloid status and
when dichotomized to tau positive or negative were 90% to 94% concordant in the populations identi-
fied. However, the schemes with fewer regions and simpler decision rules yielded more robust perfor-
mance in terms of fewer unclassified scans and increased test-retest reproducibility of assigned stage.
Discussion: Tau PET staging schemes could be useful tools to concisely index the regional involve-
ment of tau pathology in living subjects. Simpler schemes may be more robust.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Tau; PET; Flortaucipir; Alzheimer; Staging; Stage; Classification; Image; Braak; AV-1451; T8071. Introduction
Alzheimer’s disease (AD) is defined neuropathologically
by the presence of amyloid b plaques and neurofibrillary tan-
gles (NFTs) of misfolded phosphorylated tau protein [1–3].paration of this article were obtained from the Alz-
roimaging Initiative (ADNI) database (adni.loni.usc
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).Whereas amyloid plaques are widespread in the neocortex
[2], in sporadic AD, NFTs present in characteristic patterns
that suggest tau pathology begins in the entorhinal cortex
and then spreads in a largely stereotypical fashion first into
the inferior and lateral temporal cortices, followed by re-
gions in the parietal and frontal lobes, and finally the primary
sensory cortices in end-stage disease [1]. This has been codi-
fied topographically in neuropathologic tau staging schemes
[4,5].
The recent development of radiolabeled positron emis-
sion tomography (PET) ligands for tau tangles [6–8] has
enabled NFTs to be imaged in the brains of living humans.
Initial studies have demonstrated that in vivo tau PETimer’s Association. This is an open access article under the CC BY-NC-ND
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with those observed in neuropathologic studies, providing
strong prima facie evidence that these ligands reflect the
distribution of tau pathology in the living brain [9–13].
The availability of these PET tracers and other biomarkers
has stimulated the formulationof classification frameworks for
clinicalAD research based on sequential biological changes in
the brain [14–20]. These criteria enable the severity of
cognitive and functional impairment to be complemented by
objective measures of disease pathology and are refining the
concepts of both diagnosis and stage in the study of AD. To
date, much of the emphasis has been on dichotomized
biomarker measurements, indicating the presence or absence
of different pathological changes [21], exemplified most
recently by the A/T/N system based on abnormal amyloid,
tau, and/or neurodegeneration [16]. However, the stereotypical
patterns of NFT localization also allow for a more granular
regional staging of tau pathology per se, and neuropathologic
observations can inform image-based classification or staging
schemes that can be applied to tau PET images invivo [10,11].
These topographic image classification schemes provide a
concise summary of the anatomical distribution of tracer
binding that conveys the extent of regional involvement.
Interpretation of these profiles within a staging framework
rests on the assumption that certain profiles succeed others
as the disease progresses. Findings in both neuropathology
studies and emerging data with tau PET tracers support this
view, with the degree of regional involvement associated
with amyloid status, cognitive performance, and clinical
disease stage [10,13,22,23].
One of these recently described staging algorithms [10] is
based on small regions of interest (ROIs) in the anterior tem-
poral and occipital lobes and classification rules that match
as accurately as possible the 6-stage operationalized neuro-
pathologic staging scheme proposed by Braak et al. [4]. This
approach confirmed the predominance of stereotypical tau
PET patterns in individuals across the AD spectrum, but
7% of the scans in that study were not able to be matched
to one of the a priori–defined patterns, which could be a lim-
itation for prospective use of that method in clinical
research. Moreover, the very small ROIs in that scheme
are potentially sensitive to variations in image preprocess-
ing, atrophy, and experimental noise. In addition, the medial
temporal lobe (MTL) regions distinguishing stages 1–3 are
potentially prone to contamination from adjacent extrapar-
enchymal signals (e.g., optic nerve) and to tracer binding
in the choroid plexus. As a result, it may be difficult to reli-
ably distinguish between stages 1, 2, and 3 using that
method. Finally, the more advanced stages 5–6 do not cap-
ture the variability across subjects in the broader neocortical
involvement of tau in the later stages of AD.
Motivated by these limitations, we propose two simpler
tau PET staging schemes that use fewer, larger ROIs and
simplified decision rules. The first of these also targets re-
gions restricted to the anterior temporal and occipital lobes
but uses larger atlas-based masks and consolidates regionsin the MTL. The second is based on the average signal in
each of the temporal, parietal, and frontal lobes, thus sam-
plingmore of the cortex overall. The rationale for these alter-
native schemes is to improve robustness to image noise (e.g.,
test-retest), simplify implementation, and minimize unclas-
sifiable scans. In the case of the second scheme, the rationale
was also to provide more dynamic range in the assigned
stages for cases with more widespread tau load. Here, we
evaluate these two schemes, in comparison to that previously
described [10], applied to flortaucipir F 18 scans acquired in
a test-retest scenario and in the Alzheimer’s Disease Neuro-
imaging Initiative 2 (ADNI-2) study. In addition to profiling
each scheme as a staging tool, we also assess the three stag-
ing schemes when dichotomized to define each scan as tau
positive or tau negative.2. Methods
2.1. Data sets
Data from four tau imaging studies were used to form three
data sets for the present analysis. The first data set was a set of
flortaucipir F 18 scans fromN5 14 young healthy individuals
visually and quantitatively (bilateral entorhinal cortex stan-
dardized uptake value ratio [SUVr] , 1.2) determined to be
tau negative and used as a reference sample [10]. These scans
were drawn from an exploratory phase 1 study and from a
larger phase 2 study (NCT02016560) undertaken as part of
Avid Radiopharmaceuticals’ clinical development program
for the flortaucipir F 18 PET radiotracer. The second data set
was a test-retest study (N 5 21, retest interval 4–28 days) in
participants assessed as cognitively normal (CN) or diagnosed
with either mild cognitive impairment (MCI) or symptomatic
AD [24]. This data set was used to assesswithin-subject repro-
ducibility of the staging algorithms. The third data set
comprised N 5 98 participants in the ADNI-2 that received
a flortaucipir F 18 PET scan. Further details of the ADNI con-
sortium are provided in the SupplementaryMaterial. Amyloid
positivity (A1) inADNI-2 was determined from a Florbetapir
F 18 PET scan, processed by the ADNI PET core (University
of California, Berkeley) and with a cortical SUVr. 1.11. All
subjects gave informed consent.
2.2. PET image acquisition and processing
Participants received an intravenous injection of approx-
imately 10 mCi flortaucipir F 18, and PET images from four
5-minute frames between 80 and 100 minutes following the
radiotracer injection were analyzed.
The four 5-minute flortaucipir F 18 PET scans were cor-
rected for motion, averaged, and coregistered to the individ-
ual participant’s accompanying T1-weighted magnetic
resonance imaging (MRI) scan. For the ADNI-2 study, pre-
processed flortaucipir F 18 PET scans were downloaded
from the ADNI Laboratory of Neuro Imaging (http://adni.
loni.usc.edu) site. The MRI scan was spatially normalized
to the MNI152 T1 MRI template, and this transformation
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tau PET images were then transformed into SUVr images us-
ing a cerebellar gray matter reference region.2.3. Tau classification algorithms
Each of the classification schemes was based on binariz-
ing the mean SUVr signals within a predefined set of ROIs
and then seeking to match the resulting profile with expected
patterns. The three tau PET staging schemes evaluated were
as follows:
 Temporal-Occipital Classification (TOC): This
recently published approach [10] was explicitly de-
signed to mimic as closely as possible, in terms of brain
regions sampled and decision rules, the Braak 2006 op-
erationalized neuropathologic guidelines [4]. This
scheme uses small ROIs localized around the anterior
temporal lobe (hippocampus, transentorhinal cortex,
fusiform cortex, middle temporal gyrus, and superior
temporal gyrus) and in the occipital lobe (extrastriate
and primary [striate] visual cortex).
 Simplified Temporal-Occipital Classification (STOC):
This approach was developed as a simplified version of
TOC, modified to use fewer and larger ROIs from stan-
dard atlases, located in the medial, lateral, and superior
temporal lobes and in the primary visual cortex, as well
as simpler decision rules.
 Lobar classification (LC): This approach is simpler
than both TOC and STOC and uses whole-lobar
average signals from the temporal (T), parietal (P),
and frontal (F) lobes. This scheme has the fewest and
largest ROIs, sampling most of the cortical gray matter
and even simpler decision rules to assign stages.Fig. 1. Visualization of the regions of interest (ROIs) used in the three staging sch
LC. Abbreviations: HIP, hippocampus; TEC, transentorhinal cortex; FUS, fusif
EVC, extrastriate visual cortex; PVC, primary visual cortex; MTL, mesial temp
lobe; FRO, frontal lobe; TOC, Temporal-Occipital Classification; STOC, SimplifiFor the TOC scheme only, the tau PET images were gray
matter masked for compatibility with the published method
[10]. This was achieved by thresholding each individual par-
ticipant’s gray matter tissue probability map at 25% and bi-
narizing to yield an individualized gray matter mask. Gray
matter masking was not applied to the regions used in the
STOC and LC schemes as preliminary analyses suggested
that this did not improve performance. The ROIs are
illustrated in Fig. 1 and are further described in the
Supplementary Material.
For each scheme, both stereotypical and atypical ex-
pected profiles (binary patterns across the staging ROIs)
were predefined (Tables 1–3). In the case of both TOC and
STOC, these profiles included hippocampal-sparing or
medial temporal–sparing variants of the more advanced
stage patterns. In the case of LC, the number of permutations
was sufficiently low that we enumerated all possible profiles,
with those expected to reflect the stereotypical progression
of AD being T2P2F2 / T1P2F2 / T1P1F2 /
T1P1F1. Atypical patterns included T2 with P1 or F1,
and T1P2F1. For each scheme, the profiles for each hemi-
sphere were matched independently to the predefined set of
permitted patterns, and the most advanced profile was as-
signed to the scan.2.4. Thresholds for binarization
Thresholds for all schemes were determined on an
ROI-specific basis [25] with respect to the mean and standard
deviation flortaucipir F 18 SUVr values from 14 younger
healthy control subjects (age 21–31 years, average 26.2 years)
determined to be “tau negative” based on visual inspection
(the same set used in ref. [10]). Thresholds were determined
for each scheme so as to yield comparable absolute SUVremes. (A) ROIs used in TOC, (B) ROIs used in STOC, and (C) ROIs used in
orm gyrus; MTG, middle temporal gyrus; STG, superior temporal gyrus;
oral lobe; LTL, lateral temporal lobe; TEM, temporal lobe; PAR, parietal
ed Temporal-Occipital Classification; LC, lobar classification.
Table 1
Predefined patterns for the TOC scheme*
Stage
Hippocampus
(HIP)
Transentorhinal
cortex (TEC)
Fusiform
gyrus (FUS)
Middle temporal
gyrus (MTG)
Superior temporal
gyrus (STG)
Extrastriate visual
cortex (EVC)
Primary visual
cortex (PVC)
0 2 2 2 2 2 2 2
1 2 1 2 2 2 2 2
2 1 1 2 2 2 2 2
3 1 1 1 2 2 2 2
3 (HIP sparing) 2 1 1 2 2 2 2
4 1 1 1 1 2 1 2
4 (HIP sparing) 2 1 1 1 2 1 2
4 (EVC sparing) 1 1 1 1 2 2 2
4 (HIP and EVC sparing) 2 1 1 1 2 2 2
5 1 1 1 1 1 1 2
5 (HIP sparing) 2 1 1 1 1 1 2
5 (EVC sparing) 1 1 1 1 1 2 2
5 (HIP and EVC sparing) 2 1 1 1 1 2 2
6 1 1 1 1 1 1 1
6 (HIP sparing) 2 1 1 1 1 1 1
Abbreviations: TOC, Temporal-Occipital Classification; ROI, region of interest.
NOTE. Typical profiles are shown in bold and permitted atypical profiles in italics.
From ref. [10].
*A ‘1’ symbol indicates that the average signal in that ROI is above threshold, whereas a ‘2’ symbol indicates that it is below threshold.
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threshold in each ROI was defined as 2.5 standard deviations
above the mean of this reference set; this resulted in threshold
SUVr values ranging from 1.22 to 1.36 (average 1.28) [10].
For STOC, to obtain threshold SUVr values with an average
of 1.28 (range 1.24 to 1.31) as obtained for the TOC approach,
a criterion of three standard deviations above the mean of the
reference set was used. For the LC staging approach,
threshold SUVr values with a similar average of 1.28 (range
1.26 to 1.30) were also obtained using a criterion of three stan-
dard deviations above the mean of the reference set. The
threshold values, and a comparison with results obtained
with threshold values calculated as 2.5 standard deviations
above the mean for all three schemes, are provided in the
Supplementary Material.
For the purposes of dichotomizing scans to “tau negative”
(T2) or “tau positive” (T1) based on regional involvement,
we defined tau negative as stage 0–3 in TOC, stage 0–1 in
STOC, and stage 0 in LC and accordingly, tau positive asTable 2
Predefined patterns and staging rules for the STOC scheme*
Stage Medial temporal lobe (MTL) Lateral temporal lobe (L
0 2 2
1 1 2
2 1 1
2 (MTL sparing) 2 1
3 1 1
3 (MTL sparing) 2 1
4 1 1
4 (MTL sparing) 2 1
Abbreviations: STOC, Simplified Temporal-Occipital Classification; ROI, regio
NOTE. Typical profiles are shown in bold and permitted atypical profiles in ita
*A ‘1’ symbol indicates that the average signal in that ROI is above thresholdstage 4–6 in TOC, stage 2–4 in STOC, and stage 1–3 in
the LC scheme (irrespective of whether the profiles were
typical or atypical).2.5. Statistical analysis
Test-retest reliability was assessed by the percent of par-
ticipants whose stage assignment was identical on both test
and retest scans. The robustness of the staging schemes was
assessed by the number of scans that were able to be matched
to one of the predefined binarized ROI profiles. Stereotypy
of each ROI profile was quantified in the ADNI data set by
calculating the Spearman rank correlation between the pre-
dicted rank order of SUVr values and the measured rank or-
der of the difference between the individual region SUVr
values and their corresponding region-specific thresholds.
The predicted rank order was the same as the typical order
of regional involvement inscribed in the staging rules
(Tables 1–3). The average Spearman correlation acrossTL) Superior temporal gyrus (STG) Primary visual cortex (PVC)
2 2
2 2
2 2
2 2
1 2
1 2
1 1
1 1
n of interest.
lics.
, whereas a ‘2’ symbol indicates that it is below threshold.
Table 3
Predefined profiles and staging rules for the LC scheme*
Stage
Temporal
lobe (TEM)
Parietal
lobe (PAR)
Frontal
lobe (FRO)
0 (T2P2F2) 2 2 2
1 (T1P2F2) 1 2 2
2 (T1P1F2) 1 1 2
2 (T2P1F2) 2 1 2
3 (T1P1F1) 1 1 1
3 (T1P2F1) 1 2 1
3 (T2P2F1) 2 2 1
3 (T2P1F1) 2 1 1
Abbreviations: LC, lobar classification; ROI, region of interest; T, tempo-
ral; P, Parietal; F, Frontal.
NOTE. Typical profiles are shown in bold and permitted atypical profiles
in italics.
*A ‘1’ symbol indicates that the average signal in that ROI is above
threshold, whereas a ‘2’ symbol indicates that it is below threshold.
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analyses on the ADNI data set were conducted in JMP
v12.1 (SAS, Cary, NC, USA). The relationship between
assigned stages and amyloid status was assessed using an
ordinal logistic regression model for each staging scheme,
with age, disease category, and sex as additional
covariates. The relationships between regional SUVr and
global cortical SUVr values, and between assigned stages
and global cortical SUVr values, were assessed using
Pearson pairwise correlations. An alpha level of 0.05 (two
sided) was used as a threshold for statistical significance.3. Results
3.1. Participant characteristics
Both the test-retest andADNI-2 data sets contained partic-
ipants ranging from CN to demented. The test-retest data set
comprised N 5 5 (CN, age [mean6 SD] 64.8 6 9.2 years),
6 MCI (age 70.3 6 5.9 years), and 10 AD (age
74.4 6 7.3 years) participants. The ADNI-2 sample
comprisedN5 34CN (age 74.66 7.4 years; 14 amyloid pos-
itive [A1], 19 amyloid negative [A2]), 12 subjective mem-
ory complaints (age 71.7 6 4.6 years; 5 A1, 7 A2), 24
early MCI (age 75.0 6 7.5 years; 15 A1, 9 A2), 18 lateTable 4
Test-retest stability and completeness of matching to predefined profiles for the th
Data set and metric TOC
Test-retest, N (%) of subjects with unchanged stage 17/21 (81%)
Test-retest scan 1, N (%) matching predefined
profiles including permitted variants
18/21 (86%) [incl. 2/21 (1
Test-retest scan 2, N (%) matching predefined
profiles including permitted variants
18/21 (86%) [incl. 2/21 (1
ADNI-2, N (%) matching predefined profiles
including permitted variants
77/98 (79%) [incl. 11/98 (
Abbreviations: TOC, Temporal-Occipital Classification; STOC, Simplified Temp
Disease Neuroimaging Initiative 2.MCI (age 76.9 6 8.6 years; 9 A1, 7 A2), and 10 AD
(age 78.4 6 5.8 years; 9 A1, 1 A2) participants. In the
ADNI-2 data set, the amyloid status was unknown for 4%
(4/98) of participants. The characteristics of the participants
are further tabulated in the Supplementary Material.3.2. Reliability and consistency of staging schemes (test-
retest data set)
When applied to the test-retest data set, the TOC scheme
matched 86% (18/21) of both the test and retest scans to a
predefined pattern, with 10% (2/21) of each set being an
atypical profile. Across the test and retest scans, the TOC
scheme assigned the same stage to 81% (17/21) of the sub-
jects (Table 4). Of the other four, one moved from unclassi-
fied to stage 4, one from stage 4 (hippocampal sparing) to
unclassified, one from stage 0 to 4 (hippocampus and extras-
triate visual cortex sparing), and one from stage 6 to 4.
The STOC scheme matched 100% (21/21) of the scans to
a predefined pattern in both test and retest sessions, with 5%
(1/21) of each set being atypical profiles. It assigned the
same pattern to 86% (18/21) of the subjects across the test
and retest scans (Table 4). Of the other three, one moved
from stage 3 to 4, one from stage 1 to 0, and one from stage
0 to 2.
The LC scheme matched 100% (21/21) of the scans in
both test and retest sessions to a predefined stereotypical
pattern and assigned the same pattern to 95% (20/21) of
the subjects across test and retest scans (Table 4). The partic-
ipant whose assigned stage changed moved from stage
1 to 0.
The participants whose stage changed under the TOC and
STOC schemes were different individuals. The participant
whose stage changed from 1 to 0 under the LC scheme
was the same participant whose stage changed from 1 to
0 under the STOC scheme.3.3. Anatomical profiles (ADNI-2 data set)
In the ADNI sample, the TOC scheme matched 79% (77/
98) of the scans to a predefined stage pattern, with 11% (11/
98) being atypical variant profiles (Table 4). In contrast, both
the STOC and LC topographical staging schemes matchedree staging schemes
STOC LC
18/21 (86%) 20/21 (95%)
0%) atypical] 21/21 (100%) [incl. 1/21 (5%) atypical] 21/21 (100%)
0%) atypical] 21/21 (100%) [incl. 1/21 (5%) atypical] 21/21 (100%)
11%) atypical] 98/98 (100%) [incl. 5/98 (5%) atypical] 98/98 (100%)
oral-Occipital Classification; LC, lobar classification; ADNI-2, Alzheimer’s
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participants, although for STOC, 5% (5/98) of these were
MTL-sparing variants (Table 4).
The ROI profiles associated with each stage are illustrated
in Fig. 2. For the TOC scheme, the atypical variants of the
stage 3 profiles were primarily hippocampal sparing,
whereas the atypical variants of the stage 4 and 5 profiles
were mainly characterized by sparing of the extrastriate vi-
sual cortex (Fig. 2B). For the STOC scheme, in contrast to
their stereotypical stage counterparts, the MTL-sparing pro-
files were overall perithreshold (Fig. 2C). With the LC
scheme, using temporal, parietal, and frontal lobes only,
100% (98/98) of the cases evidenced a stereotypical profile
(Table 4).
Mean SUVr images for all subjects assigned the same
stage are shown in Fig. 3, illustrating the whole brain pat-
terns beyond the specific ROIs used for classification. The
precuneus and posterior cingulate cortex, along with the or-
bitofrontal and anterior cingulate cortices, are minimally
involved for stages classified as having tau in the MTL but
not the lateral temporal lobe, but have notably increased
signal at stages corresponding to the presence of tau outside
the MTL (TOC stage 4 and STOC stage 2).
The degree of stereotypy in the sequential regional
involvement of the regions used in each of the staging
schemes is illustrated in Fig. 4. In all three schemes, higher
global cortical SUVr (which ranged from 0.89 to 1.78) wasFig. 2. Mean ROI profiles for each assigned stage across the three staging schemes
and (C) LC schemes. (D, E) Atypical vs. typical profiles observed for (D) TOC a
heimer’s Disease Neuroimaging Initiative; TOC, Temporal-Occipital Classification
tion; PVC, primary visual cortex; EVC, extrastriate visual cortex; STG, super
TEC, transentorhinal cortex; HIP, hippocampus; MTL, mesial temporal lobe;
FRO, frontal lobe; SUVr, standardized uptake value ratio.associated with positivity in more of the staging regions,
with more of the “later” regions being positive as the global
SUVr increases. SUVr values in the individual ROIs were
also associated with global cortical SUVr (R2 5 0.15–0.76
for TOC, 0.28–0.81 for STOC, and 0.76–0.87 for LC),
with the weakest associations in TOC and STOC observed
for the occipital cortex ROIs. When the scans were ranked
by the order in which each region becomes positive, in the
order encoded in the staging schemes, the patterns reveal a
predominant stereotypy overall, wherein “later” regions
turn positive only when “earlier” regions are already so.
This relationship was cleanest for the LC scheme. Consistent
with these observations, when quantified using Spearman
rank correlations, the average stereotypy values in the left
and right hemispheres were 0.32 and 0.36 for TOC, 0.76
and 0.74 for STOC, and 0.89 and 0.91 for the LC scheme.
The assigned stages were significantly associated with
global cortical SUVr for all three schemes (TOC:
R2 5 0.41, P , .0001; STOC: R2 5 0.48, P , .0001; LC:
R2 5 0.62, P , .0001). The relationship was cleanest for
the LC scheme with a monotonic and near-linear relation-
ship observed between LC stage and global SUVr (Fig. 5).3.4. Relationship to disease stage and amyloid status
The distribution of assigned tau PET stages across disease
stage and amyloid status is illustrated for each stagingin the ADNI-2 data set. (A–C) Typical patterns for the (A) TOC, (B) STOC,
nd (E) STOC schemes. Abbreviations: ROI, region of interest; ADNI, Alz-
; STOC, Simplified Temporal-Occipital Classification; LC, lobar classifica-
ior temporal gyrus; MTG, middle temporal gyrus; FUS, fusiform gyrus;
LTL, lateral temporal lobe; TEM, temporal lobe; PAR, parietal lobe;
Fig. 3. Mean SUVr maps by assigned stage for the three classification schemes in the ADNI-2 data set. (A) TOC, (B) STOC, and (C) LC shown for left hemi-
sphere. Typical and atypical images for each stage are combined here but are presented separately in the Supplementary Material. Abbreviations: ADNI-2,
Alzheimer’s Disease Neuroimaging Initiative 2; TOC, Temporal-Occipital Classification; STOC, Simplified Temporal-Occipital Classification; LC, lobar clas-
sification; SUVr, standardized uptake value ratio.
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aging stages were significantly more prevalent in amyloid
positive than amyloid negative participants (TOC,
P 5 .00029; STOC, P 5 .00013; LC, P , .0001). There
was no significant association between disease stage and
tau PET stage.
When the classification results were dichotomized to T2
or T1, there was a high degree of concordance across the
three schemes. Of the 79% (77/98) scans for which the
TOC scheme was able to match a profile, 65% (50/77)
were classified as T2 and 35% (27/77) T1. Both the
STOC and LC schemes classified 61/98 (62%) subjects as
T2 and 37/98 (38%) as T1. There was a 92% concordance
between TOC and STOC, 94% between TOC and LC, and
90% between STOC and LC (where the concordance with
TOC was calculated only on the 77 scans for which a stage
was available for both).
Of the participants whose amyloid status was known,
96%, 82%, and 91% of the subjects classified as T1 by
TOC, STOC, and LC, respectively, were also A1; in
contrast, 41%, 40%, and 35% of subjects classified as T2
by the three methods were A1.4. Discussion
Image-based topographic tau PET staging schemes can
provide a concise summary of how the tau PET signal is
distributed across AD-related brain regions and might be a
useful complement to other biomarkers and clinical assess-
ments. We evaluated three different topographic staging
schemes on flortaucipir F 18 scans in a test-retest scenarioand from subjects from the ADNI-2 tau PET pilot study.
The three schemes were largely consistent (90%–94%
concordance) when dichotomized to categorize scans as
T2 or T1. Most (82%–96%) of individuals determined as
T1were also A1, in contrast to only 35% to 41% of individ-
uals determined as T2. Overall, moving toward fewer, larger
ROIs and simpler decision rules resulted in more consistent
stage assignments across test and retest scans and fewer un-
classified or atypical profiles.
The TOC and STOC schemes have most of their dynamic
range associated with the earlier phases of AD-related tau
accumulation, distinguishing differential involvement of
anterior temporal lobe regions before substantial spread to
the wider neocortex. The STOC scheme did not attempt to
distinguish differential involvement of mesial temporal sub-
regions captured in TOC stages 1–3 because these may be a
feature of normal aging [26] and the onset of measurable
cognitive symptoms may be associated with the appearance
of tau in the lateral temporal regions [9]. Other brain regions
commonly observed in association with tau outside the
mesial temporal lobe, such as the precuneus and orbitofron-
tal cortex, and visible in the stage-specific images in Fig. 3,
were not explicitly used in these schemes. However, a wide
range of neocortical tau patterns are unlikely to be distin-
guished by the more advanced TOC or STOC stages.
Thus, classification schemes like TOC or STOC might be
more useful in the study of populations very early in the
course of disease (e.g., preclinical AD), where sensitivity
to the early spread of tau in the anterior temporal lobe may
be of particular interest. However, the present study shows
that this sensitivity to more precise regional involvement
Fig. 4. Stereotypy of regional profiles for the three staging schemes in the ADNI-2 data set. Relationship between regional positivity in the regions used in the
TOC (A), STOC (B), and LC (C) regional staging schemes in the ADNI-2 data set. Each column represents an individual scan, with regional positivity reflected
by dark shading. In (A), scans that did not match an expected profile are shaded in dark blue. In (C), occipital lobe region positivity is shown in orange as it was
not formally used in the LC staging scheme. Regions depicted are bilateral averages; similar patterns were observed when considering each hemisphere
independently—see Supplementary Material. Abbreviations: SUVr, standardized uptake value ratio; ADNI-2, Alzheimer’s Disease Neuroimaging Initiative
2; TOC, Temporal-Occipital Classification; STOC, Simplified Temporal-Occipital Classification; LC, lobar classification.
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to image noise. In contrast, the LC scheme is likely to be
relatively insensitive to differential levels of tau localized
to the anterior temporal lobe but, given its more linear rela-Fig. 5. Relationship between assigned stages and global average SUVr for the thre
and (C) LC stage. In each group, the boxes summarize 25th, 50th, and 75th percen
atypical profiles are included in the TOC (A) and STOC (B) graphs. Abbreviations
roimaging Initiative 2; TOC, Temporal-Occipital Classification; STOC, Simplifietionship with global tau burden and explicit sampling of the
wider neocortex, may have more utility in the more
advanced stages of tau accumulation. It is also likely that
the larger ROIs used in the LC method are relativelye staging schemes in the ADNI-2 data set. (A) TOC stage, (B) STOC stage,
tiles, and the whiskers extend from minimum to maximum. Both typical and
: SUVr, standardized uptake value ratio; ADNI-2, Alzheimer’s Disease Neu-
d Temporal-Occipital Classification; LC, lobar classification.
Fig. 6. Distribution of assigned tau PET stages across clinical diagnostic categories and amyloid status in the ADNI-2 data set. (A–C) Typical profiles estimated
using (A) TOC, (B) STOC, and (C) LC staging; (D, E) atypical profiles estimated using (D) TOC and (E) STOC. (F) Mean6 standard error of the mean of the
global cortical average SUVr, by diagnostic category and amyloid status. Abbreviations: PET, positron emission tomography; SUVr, standardized uptake value
ratio; ADNI-2, Alzheimer’s Disease Neuroimaging Initiative 2; TOC, Temporal-Occipital Classification; STOC, Simplified Temporal-Occipital Classification;
LC, lobar classification; A1, amyloid positive; A2, amyloid negative; CN, cognitively normal; SMC, subjective memory complaint; EMCI, early MCI; LMI,
late MCI; AD, Alzheimer’s disease.
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within subjects and to localized variations in tau pattern be-
tween subjects.
In the LC scheme, positivity in the occipital lobe was
found in a subset of scans in conjunction with all observed
combinations of temporal, parietal, and frontal lobe positiv-
ity in the present study. This may be because the whole oc-
cipital lobe includes contributions from both lateral and
medial parts of the occipital lobe, which can be involved
at different stages of tau spread in AD [4]. Occipital lobe
tau binding may indicate posterior cortical atrophy [27,28]
or might also represent a contribution from concomitant
Lewy body pathology, as indicated by a recent tau imaging
study in Lewy body dementia [29] and observed occipital
hypometabolism noted in individuals with pathologically
confirmed Lewy body copathology [30].
The thresholds used for ROI-wise binarization in this
study were chosen for consistency with our previous report
[10]. The use of lower thresholds would result in more
ROIs being positive and would be expected to shift the over-
all distribution of assigned stages higher. However, it may
also lead to increased “false positive” ROIs and potentially
to an increased number of profiles that do not fit an expected
pattern. The threshold value(s) will also likely depend on the
SUVr reference region. In particular, a flortaucipir reference
region based on pixels exhibiting behavior suggestive of
nonspecific binding in the white matter has recently been
proposed for flortaucipir F 18 scans [31]. The question of
threshold definition remains open. Clinical correlations
and relationship to disease progression can provide informa-
tion on the thresholds that may be most clinically relevant.
The predominantly stereotypical presentation of tau pa-
thology in AD is the primary rationale behind topographicstaging schemes. However, neuropathology studies have
also noted some degree of case-to-case variability [1,4,5],
and others have proposed specific subtypes of AD based
on variant presentations of tau (e.g., hippocampal sparing
or limbic predominant) [32]. The TOC and STOC schemes
both allowed for limited number of atypical profiles, mainly
based on sparing of medial temporal structures or the extras-
triate visual cortex. Recent tau PET imaging studies in atyp-
ical variants of AD (such as logopenic variant primary
progressive aphasia, posterior cortical atrophy, and early-
onset AD) have shown anatomical profiles of flortaucipir F
18 binding that differ still more substantially from those
observed in amnestic AD [27,33–35]. The LC approach
may be best placed to identify these AD variants that
appear to have distinct tau PET presentations in the
neocortex that can be efficiently summarized on the basis
of differential lobar involvement.
Although this PET tracer exhibits robust test-retest per-
formance when assessed using conventional regional
methods [24], the three staging schemes assessed here evi-
denced different sensitivity to scan-to-scan variability in
SUVr. The TOC scheme had the worst test-retest consis-
tency in assigned stages, with quite different stage classifica-
tions observed for some subjects (e.g., stage 0 to atypical
stage 4). It is likely that this reflects both the small size of
the ROIs (with potential contributions from both inherent
signal variability and slight scan-to-scan differences in im-
age alignment) and the number of ROIs on which the staging
is based (higher chance of a variability-induced change be-
tween positive and negative in one or more of the regions
when the signal intensities are perithreshold). The results
with the STOC and LC schemes bear out our hypothesis
that a combination of larger regions (reducing the test-
A.J. Schwarz et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 221-231230retest variability in image noise per se) and fewer regions
(reducing the combinatorial chances of a perithreshold
signal changing state) would result in a more robust perfor-
mance. These findings also highlight the importance of as-
sessing test-retest variability of staging and other
analytical methods that depart from conventional ROI
analyses.
Limitations of the present study include the limited sam-
ple sizes, especially in the more severely symptomatic cat-
egories (amnestic MCI and AD). Whereas the results with
the TOC scheme were qualitatively consistent with those
previously reported in an independent data set [10], further
study of these approaches in other data sets is warranted.
The staging schemes were designed to assess AD-related
tau pathology and assessed here only in well-defined
research cohorts targeting older participants in the aged
or sporadic AD spectrum; their applicability and perfor-
mance in more general aging populations, early-onset, or
autosomal-dominant patients or in clinical practice remains
to be evaluated.
In conclusion, tau PET staging schemes could be useful
tools to concisely index the regional involvement of tau
pathology in living subjects and as the basis of a dichot-
omized definition of tau positive or tau negative. Simpler
schemes are likely to be more robust. Algorithms such as
STOC based on temporal lobe subregions may be more
sensitive to early AD-related tau spread, whereas sampling
the wider neocortex such as in the LC scheme may be
more useful in participants with a greater overall tau
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1. Systematic review: The literature on neuropathology
and more recent positron emission tomography
(PET) imaging reports of the presentation of tau pa-
thology in the human brain and its association with
aging and clinical presentations of Alzheimer’s dis-
ease was reviewed via PubMed search. Specifically,
previous work on how Alzheimer’s disease tau pat-
terns can be interpreted within a disease staging
framework were evaluated.
2. Interpretation: Our work adds to the body of knowl-
edge in this area by assessing methodological robust-
ness (including test-retest reliability) and association
with disease stage and amyloid status of three in vivo
tau PET staging schemes.
3. Future directions: It will be important to test the
generalizability of these findings as more tau PET
data accumulate, including with other tau PET radio-
tracers, and to evaluate the optimal choice of binar-
ization threshold.References
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